Spatial Genomics and Transcriptomics Market Size

Spatial Genomics & Transcriptomics Market Analysis

During the time frame of the forecast, the spatial genomics and transcriptomics market is expected to register an annual rate of 8.2%.
COVID-19 had a notable impact on the spatial genomics and transcriptomics markets during the pandemic period. The growing use of spatial genomics and transcriptomics in COVID-19 diagnosis to obtain appropriate treatments, as well as the development of COVID-19 prevention strategies, has had a significant impact on market growth.For instance, the article published in Nature in March 2021 mentioned that spatial transcriptomic data from COVID-19 patient autopsy tissues revealed distant ACE2 expression loci with macrophage and neutrophil infiltration in the lungs. The article also mentioned that these findings can inform public health and may help develop and drive SARS-CoV-2 diagnostic and prevention treatment strategies. Such increased adoption of spatial genomics and transcriptomics in the diagnosis of COVID-19 had a notable impact on the growth of the market during the pandemic period. Also, the demand for spatial genomics and transcriptomics is expected to remain intact due to the emergence of mutant strains of the COVID-19 virus during the post-pandemic period, thereby contributing to the growth of the market over the forecast period.



The spatial genomics and transcriptomics market is expected to grow owing to the emerging potential of spatial genomic analysis as a cancer diagnostic tool and the advent of the fourth generation of sequencing. For instance, in the Frontiers Journal article published in October 2022, spatial transcriptomics was described as a benefit for identifying and comprehensively understanding special spatial areas such as tumor interfaces and tertiary lymphoid structures. The report also mentioned that spatial transcriptomics also showed great potential to improve pathological diagnosis and identify novel prognostic factors in cancer. Such benefits of spatial genomics and transcriptomics for the detection of cancer are expected to drive the growth of the studied market.



Also, the increasing product launches and investments by various market players to develop advanced spatial genomics and transcriptomics technologies are expected to fuel the market's growth rate. For instance, in June 2022, 10x Genomics announced a series of product updates, such as Chromium, Visium, Xenium, and others, that will be presented at the 2022 AGBT general meeting in Orlando. Also, in February 2022, Fulgent Genetics invested in Spatial Genomics Inc. to develop the company's multi-omics platform and seqFISH technology for Fulgent's comprehensive suite of genomic testing solutions.



However, slow implementation of technology and well-established workflows for conventional genomics and transcriptomics analysis are expected to hinder market growth.